blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3534885

EP3534885 - FARNESYLTRANSFERASE INHIBITORS FOR USE IN TREATING CANCER [Right-click to bookmark this link]
Former [2019/37]FARNESYLTRANSFERASE INHIBITORS FOR USE IN METHODS OF TREATING CANCER
[2020/36]
StatusNo opposition filed within time limit
Status updated on  26.11.2021
Database last updated on 13.11.2024
FormerThe patent has been granted
Status updated on  18.12.2020
FormerGrant of patent is intended
Status updated on  12.08.2020
FormerExamination is in progress
Status updated on  03.03.2020
FormerRequest for examination was made
Status updated on  09.08.2019
FormerThe international publication has been made
Status updated on  11.05.2018
Formerunknown
Status updated on  03.03.2018
Most recent event   Tooltip03.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 05.06.2024  [2024/23]
Applicant(s)For all designated states
Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130 / US
[2021/02]
Former [2019/37]For all designated states
Kura Oncology, Inc.
3033 Science Park Road, Suite 220
San Diego, CA 92121 / US
Inventor(s)01 / GUALBERTO, Antonio
8 Larch Road
Acton, MA 01720 / US
02 / SCHOLZ, Catherine Rose
8 James Millen Road
North Reading, MA 01864 / US
 [2019/37]
Representative(s)Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
[2019/37]
Application number, filing date17842428.902.11.2017
[2019/37]
WO2017US59686
Priority number, dateUS201662417044P03.11.2016         Original published format: US 201662417044 P
[2019/37]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2018085518
Date:11.05.2018
Language:EN
[2018/19]
Type: A2 Application without search report 
No.:EP3534885
Date:11.09.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 11.05.2018 takes the place of the publication of the European patent application.
[2019/37]
Type: B1 Patent specification 
No.:EP3534885
Date:20.01.2021
Language:EN
[2021/03]
Search report(s)International search report - published on:EP12.07.2018
ClassificationIPC:A61K31/4709, A61K31/00, A61P35/00, A61P35/04, C12Q1/68, C12Q1/6886
[2020/36]
CPC:
C12Q1/6886 (EP,EA,KR,US); A61K31/4709 (EP,EA,KR,US); A61K31/00 (EP,EA,US);
A61P35/00 (EP,EA,KR,US); A61P35/04 (EP,EA,US); C12Q1/68 (EA,US);
C12Q2531/113 (KR); C12Q2600/106 (EP,EA,KR,US); C12Q2600/156 (EP,EA,KR,US) (-)
Former IPC [2019/37]A61K31/00, A61K31/4709, A61P35/00, A61P35/04, C12Q1/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/37]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:FARNESYLTRANSFERASE-INHIBITOREN ZUR VERWENDUNG BEI DER BEHANDLUNG VON KREBS[2020/36]
English:FARNESYLTRANSFERASE INHIBITORS FOR USE IN TREATING CANCER[2020/36]
French:INHIBITEURS DE FARNÉSYLTRANSFÉRASE POUR UTILISATION DANS LE TRAITEMENT DE CANCER[2020/36]
Former [2019/37]FARNESYLTRANSFERASE-HEMMER ZUR BEHANDLUNG VON KREBS
Former [2019/37]FARNESYLTRANSFERASE INHIBITORS FOR USE IN METHODS OF TREATING CANCER
Former [2019/37]MÉTHODES DE TRAITEMENT DE PATIENTS CANCÉREUX PAR INHIBITEURS DE FARNÉSYLTRANSFÉRASE
Entry into regional phase30.04.2019National basic fee paid 
30.04.2019Designation fee(s) paid 
30.04.2019Examination fee paid 
Examination procedure30.04.2019Examination requested  [2019/37]
30.04.2019Date on which the examining division has become responsible
18.12.2019Amendment by applicant (claims and/or description)
06.03.2020Despatch of a communication from the examining division (Time limit: M04)
03.07.2020Reply to a communication from the examining division
13.08.2020Communication of intention to grant the patent
08.12.2020Fee for grant paid
08.12.2020Fee for publishing/printing paid
08.12.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20212873.2  / EP3838275
Opposition(s)21.10.2021No opposition filed within time limit [2021/52]
Fees paidRenewal fee
14.11.2019Renewal fee patent year 03
13.11.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL20.01.2021
CY20.01.2021
EE20.01.2021
MK20.01.2021
BG20.04.2021
[2024/23]
Former [2023/30]AL20.01.2021
CY20.01.2021
EE20.01.2021
BG20.04.2021
Former [2022/07]AL20.01.2021
EE20.01.2021
BG20.04.2021
Former [2021/48]EE20.01.2021
BG20.04.2021
Former [2021/36]BG20.04.2021
Cited inInternational search[XY]WO2015164862  (SLOAN KETTERING INST CANCER [US]) [X] 32,33,36-39,41,49,50 * page 1, paragraph [0001] * * page 2, paragraphs [0005]-[0006] * * page 9, paragraphs [0037]-[0038] * * page 10, paragraph [0041] * * claims 1, 6, 8, 9, 10, 13, 14, 16-18 * [Y] 1-91;
 [XPI]WO2017031101  (KURA ONCOLOGY INC [US]) [XP] 32-45,49,50,76-86,90,91 * page 7, paragraph [0029] * * page 8, paragraph [0034] * * page 31, paragraph [0092] * * page 116, paragraph [00359] * * page 170, paragraph [00540] * * pages 170-171, paragraph [00545] * * pages 173-174, paragraph [00556] * * example X * * claims 1-11, 17-19, 26 * [I] 1-31,46-48,51-75,87-89;
 [Y]  - BRAIG FRIEDERIKE ET AL, "Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma", ONCOTARGET, (20160712), vol. 7, no. 28, pages 42988 - 42995, XP002780734 [Y] 1-50 * abstract * * page 42989, column 2, paragraphs 1-2 * * page 42991, column 1, paragraph 1 * * figure 2 * * page 42992, column 2, paragraph 2 *
 [Y]  - J Vachtenheim ET AL, "Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung", Clinical Cancer Research, UNITED STATES, vol. 1, (19950301), pages 359 - 365, URL: http://clincancerres.aacrjournals.org/content/clincanres/1/3/359.full.pdf, (20180502), XP055472173 [Y] 51-91 * abstract * * page 359, column 2, paragraph 2 - page 360, column 1, paragraph 2 *
 [IY]  - anonymous, "Hisory of Changes for Study NCT02383927 Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations", (20160912), page 8pp, Clinical Trials.gov archive, URL: https://clinicaltrials.gov/ct2/history/NCT02383927?V_7=View#StudyPageTop, (20180502), XP002780735 [I] 32,36,37,49,50 * pages 2-5 * [Y] 1-50
 [XPI]  - HO, ALAN LOH (CORRESPONDENCE) ET AL, "An open-label, phase II study of tipifarnib for the treatment of and neck.", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20170620), Database accession no. 0052654131, URL: STN, XP002780736 [XP] 32,49,50,76,90,91 * abstract * [I] 1-91
by applicantUS3536809
 US3598123
 US3845770
 US3916899
 US4008719
 US4016043
 US4018653
 US4044126
 US4328245
 US4364923
 US4409239
 US4410545
 US4414209
 US4424279
 US4870287
 US5033252
 US5052558
 US5059595
 US5073543
 WO9208800
 US5120548
 US5210015
 US5238922
 WO9318186
 US5310652
 WO9410138
 US5322770
 US5323907
 US5354556
 US5399491
 US5409818
 US5420245
 US5437990
 US5455166
 US5487972
 US5491164
 US5491063
 US5504212
 US5523430
 US5532359
 US5534537
 US5561058
 US5571673
 US5578629
 US5585359
 US5591767
 US5602098
 US5639476
 US5639480
 US5641864
 US5661161
 WO9730992
 US5674533
 US5693517
 US5700806
 US5721236
 US5733566
 US5739108
 US5750567
 US5756528
 US5760395
 US5767274
 US5773455
 WO9828303
 US5780492
 US5804375
 US5807852
 US5843941
 US5852010
 US5856439
 US5856326
 US5859015
 US5861529
 US5869682
 US5872135
 US5874442
 US5880140
 US5889053
 US5891889
 US5891474
 US5922356
 US5936097
 US5939557
 WO9945712
 WO9945912
 US5958939
 US5965578
 US5965539
 US5968965
 US5968952
 US5972984
 US5972966
 US5972891
 US5976851
 US5980945
 US5993855
 WO0001691
 WO0012498
 WO0012499
 US6037350
 US6045830
 US6087324
 US6113943
 US6169096
 US6177432
 US6187786
 US6197350
 US6248363
 US6264970
 US6267981
 US6376461
 US6419961
 US6545020
 US6589548
 US6613358
 US6699500
 US6740634
 US6838467
 US6927024
 US7101663
 US7122799
 US2007048782
 US7186507
 US7932036
    - LANCET et al., Blood, (20060000), vol. 2, page 2
    - THERASSE et al., "New guidelines to evaluate the response to treatment in solid tumors", JNCI, (20000000), vol. 92, no. 3, pages 205 - 216
    - BERNDT et al., Nature Reviews Cancer, vol. 11, pages 775 - 91
    - SHEFFIELD et al., Ped Dev Pathology, (20150000), vol. 18, pages 237 - 244
    - TSUKUDA et al., Biochem Biophys Res Commun, (20000000), vol. 278, pages 653 - 58
    - "GENBANK", Database accession no. CR536579.1
    - "GENBANK", Database accession no. GI:49168641
    - RAPONI et al., Blood, (20080000), vol. 111, pages 2589 - 96
    - SHEN et al., Drug Disc. Today, (20150000), vol. 20, page 2
    - DUEZ, S. et al., Bioorg. Med. Chem., (20100000), vol. 18, pages 543 - 556
    - KOHL, N.E. et al., PNAS, (19940000), vol. 91, pages 9141 - 9145
    - LEE, H-Y. et al., Bioorg. Med. Chem. Lett., (20020000), vol. 12, pages 1599 - 1602
    - HAROUSSEAU et al., Blood, (20090000), vol. 114, pages 1166 - 1173
    - THOMAS et al., Biologies, (20070000), vol. 1, pages 415 - 424
    - APPELS et al., The Oncologist, (20050000), vol. 10, pages 565 - 578
    - JENS T. CARSTENSEN, Drug Stability: Principles & Practice, Marcel Dekker, (19950000), pages 379 - 80
    - SEFTON, CRC Crit. Ref. Biomed. Eng., (19870000), vol. 14, page 201
    - BUCHWALD et al., Surgery, (19800000), vol. 88, page 507
    - SAUDEK et al., N. Engl. J. Med., (19890000), vol. 321, page 574
    - GOODSON, Medical Applications of Controlled Release, (19840000), vol. 2, pages 115 - 138
    - LANGER, Science, (19900000), vol. 249, pages 1527 - 1533
    - CHENG DT et al., J Mol Diagn., (20150000), vol. 17, no. 3, pages 251 - 64
    - ZUJEWSKI J., J Clin Oncol., (20000200), vol. 18, no. 4, pages 927 - 41
    - LARA PN JR., Anticancer Drugs., (20050000), vol. 16, no. 3, pages 317 - 21
    - KIRSCHBAUM MH, Leukemia, (20111000), vol. 25, no. 10, pages 1543 - 7
    - KURZROCK, Clin Cancer Res, (20080000), vol. 14, no. 2, page 509
    - KARP et al., Blood, (20010000), vol. 97, pages 3361 - 3369
    - MESA, Lancet Oncol, (20060000), vol. 6, pages 279 - 286
    - RAO et al., J Clin Oncol, (20040000), vol. 22, pages 3950 - 3957
    - RAPONI et al., Clin Cancer Res., (20070000), vol. 13, pages 2254 - 60
    - KAMASANI et al., Cancer Biology & Therapy, (20070000), vol. 6, pages 1418 - 1423
    - LANCET et al., Blood (ASH, (20120000), vol. 120
    - PARKER; BARNES, Methods in Molecular Biology, (19990000), vol. 106, pages 247 - 283
    - HOD, Biotechniques, (19920000), vol. 13, pages 852 - 854
    - WEIS, Trends in Genetics, (19920000), vol. 8, pages 263 - 264
    - WU; WALLACE, Genomics, (19880000), vol. 4, pages 560 - 569
    - WALKER et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 392 - 396
    - KWOH et al., Proc. Natl. Acad. Sci. USA, (19890000), vol. 86, pages 1173 - 1177
    - GUATELLI et al., Proc. Natl. Acad. Sci. USA, (19900000), vol. 87, pages 1874 - 1878
    - KRAMER; LIZARDI, Nature, (19890000), vol. 339, pages 401 - 402
    - LOMELI et al., Clin. Chem., (19890000), vol. 35, pages 1826 - 1831
    - ABRAMSON; MYERS, Current Opinion in Biotechnology, (19930000), vol. 4, pages 41 - 47
    - BUSTIN et al., Clin. Sci., (20050000), vol. 109, pages 365 - 379
    - HOLLAND et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 88, pages 7276 - 7280
    - KENT, W., Genome Res., (20020000), vol. 12, no. 4, pages 656 - 64
    - "Primer3 on the WWW for general users and for biologist programmers", ROZEN; SKALETSKY, Bioinformatics Methods and Protocols: Methods in Molecular Biology, Humana Press, (20000000), pages 365 - 386
    - "General Concepts for PCR Primer Design", DIEFFENBACH, PCR Primer, A Laboratory Manual, Cold Spring Harbor Laboratory Press, (19950000), pages 133 - 155
    - "Optimization of PCRs", INNIS; GELFAND, PCR Protocols, A Guide to Methods and Applications, CRC Press, (19940000), pages 5 - 11
    - PLASTERER, T. N., "Primerselect: Primer and probe design", Methods Mol. Biol., (19970000), vol. 70, pages 520 - 527
    - WANG et al., Nature Reviews Genetics, (20090100), vol. 10, no. 1, pages 57 - 63
    - RYAN et al., BioTechniques, (20080000), vol. 45, no. 1, pages 81 - 94
    - MAHER et al., Nature, (20090100), vol. 458, no. 7234, pages 97 - 101
    - SCHENA et al., Proc. Natl. Acad. Sci. USA, (19960000), vol. 93, no. 2, pages 106 - 149
    - VELCULESCU, Science, (19950000), vol. 270, pages 484 - 487
    - VELCULESCU et al., Cell, (19970000), vol. 88, pages 243 - 51
    - KALLIONIEMI et al., Science, (19920000), vol. 258, pages 818 - 821
    - GALL et al., Meth. Enzymol., (19810000), vol. 21, pages 470 - 480
    - ANGERER et al., Genetic Engineering: Principles andMethods, Plenum Press, (19850000), vol. 7, pages 43 - 65
    - Methods in Cell Biology: Antibodies in Cell Biology, (19930000), vol. 37
    - KAMARCH, Methods Enzymol, (19870000), vol. 151, pages 150 - 165
    - LIANG C et al., Cancer Res., (20120000), vol. 72, pages 5004 - 5013
    - MESA, Expert Rev Anticancer Ther., (20060000), vol. 6, pages 313 - 90
    - SARANATH et al., Br J Cancer, (19910000), vol. 63, pages 573 - 578
    - ANDERSON et al., J Otolaryngol, (19920000), vol. 21, pages 321 - 326
    - ANDERSON et al., Arch Otolaryngol Head Neck Surg, (19940000), vol. 120, pages 755 - 760
    - Nat Commun, (20130000), vol. 4, page 2873
    - Nature, (20150000), vol. 517, pages 576 - 582
    - HANRAHAN et al., Am J Clin Oncol., (20090000), vol. 32, pages 274 - 9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.